Bausch + Lomb debuts eye vitamins to help protect against blue light
Bausch + Lomb, a global eye health company and subsidiary of Valeant Pharmaceuticals International, announced on Wednesday the development of its new Ocuvite Blue Light eye vitamins.
Ocuvite Blue Light eye vitamins contain 25 milligrams of lutein and five milligrams of zeaxanthin isomers, the key eye nutrients that help absorb blue light before it reaches the macula, which is responsible for our central vision.
“With the increasing number of hours Americans are spending on digital devices, there is a growing need for a product that helps our eyes filter the blue light that is emitted from these devices,” said Joseph Gordon, president, Consumer Healthcare and Vision Care, Bausch + Lomb. “Ocuvite® Blue Light is specifically formulated to meet this need and help consumers maintain their eye health in our screen-centric world.”
Ocuvite Blue Light eye vitamins will be available for purchase in the vitamin and eye care aisles at major retailers in the third quarter of 2018 and have a suggested retail price of $16.99.
New sesame seed energy bar hits market
Absolutely Gluten Free, a manufacturer of gluten-free, all-natural crackers, flatbreads, and pizza, is taking on the energy bar category with the launch of TahiniBAR, a grab-and-go sesame seed snack that weighs in at only 100 calories.
All varieties — Cocoa Nibs, Pistachio and Vanilla — are certified OU Kosher and dairy free.
Like tahini and its decadent dessert cousin halvah, the energy bars are made from all-natural roasted sesame seeds. Sesame seeds help boost energy levels and are a good source of vitamins, minerals, protein, fiber, calcium, iron, zinc and potassium.
The bars are sold in packs of seven 4.4-oz. sizes. The suggested retail price is $3.99 per seven-bar pack.
Roche introduces self-testing device for coagulation monitoring
Roche is planning to make its new CoaguChek Vantus system, the first self-testing device for coagulation monitoring with built in Bluetooth technology, commercially available this summer.
With the new system, patients will be able to use their tablet or smartphone with a compatible app to send their results automatically via wireless connectivity, which enables healthcare providers to receive patient INR results rapidly and accurately, while also reducing visits to the lab.
“As healthcare systems face continued pressure to deliver improved access to care at a lower cost, increased connectivity between healthcare providers and patients becomes even more important,” said Alan Wright, chief medical officer, Roche Diagnostics. “This innovative technology sets the standard in coagulation monitoring by providing high quality, convenient testing, while optimizing the patient result reporting workflow.
Self-testing can enable patients to test more conveniently, which may improve their time in the target INR range set by their doctor as compared with in-office or lab testing. And when compared with lab testing, patient self-testing has been correlated with fewer thromboembolic events.
Self-testing provides patients with the tools and flexibility to be more engaged in their therapy and this supports better compliance. In addition, self-testing can also help patients stay connected to their doctor, who can quickly receive the results following the patient’s self-test.